July 14, 2016 / 8:22 PM / a year ago

BRIEF-Revance Therapeutics plans to initiate global phase 3 program in second half of 2016

July 14 (Reuters) - Revance Therapeutics Inc :

* Revance Announces Completion Of Pre-Phase 3 meeting with FDA for rt002 injectable to treat glabellar lines

* Company plans to initiate global phase 3 program in second half of 2016

* Co’s phase 3 program will include two placebo-controlled pivotal studies conducted at multiple sites in US and Canada Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below